| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6054430 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US7199098 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US6362161 | TEVA PHARMS USA | Copolymer-1 improvements on compositions of copolymers |
May, 2014
(9 years ago) | |
| US8367605 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5981589 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US6054430 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US6342476 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US6362161 | TEVA PHARMS USA | Copolymer-1 improvements on compositions of copolymers |
May, 2014
(9 years ago) | |
| US6620847 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US6939539 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US7199098 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US8367605 | TEVA PHARMS USA | Copolymer-1 improvements in compositions of copolymers |
May, 2014
(9 years ago) | |
| US9402874 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US9155776 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US8232250 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US8399413 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
| US8969302 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(6 years from now) | |
Copaxone is owned by Teva Pharms Usa.
Copaxone contains Glatiramer Acetate.
Copaxone has a total of 17 drug patents out of which 12 drug patents have expired.
Expired drug patents of Copaxone are:
- US5981589
- US6054430
- US6342476
- US6362161
- US6620847
- US6939539
- US7199098
- US8367605
- US6054430
- US7199098
- US6362161
- US8367605
Copaxone was authorised for market use on 20 December, 1996.
Copaxone is available in injectable;subcutaneous, for solution;subcutaneous dosage forms.
Copaxone can be used as method of treating ms by administering copaxone.
The generics of Copaxone are possible to be released after 19 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 28, 2017 |
| New Indication(I-594) | Feb 27, 2012 |
Drugs and Companies using GLATIRAMER ACETATE ingredient
Market Authorisation Date: 20 December, 1996
Treatment: Method of treating ms by administering copaxone
Dosage: INJECTABLE;SUBCUTANEOUS; FOR SOLUTION;SUBCUTANEOUS
COPAXONE family patents
